Latest Period
Q1 2026
Security Snapshot
Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) Institutional Ownership
CUSIP: 68235C206
13F Institutional Holders and Ownership History from Q2 2023 to Q1 2026
Institutions Reporting
41
Shares (Excl. Options)
18,938,098
Price
$3.28
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, no par value
- Symbol
- IMDX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 18,938,098
- Total 13F value
- $62,116,945
- Portfolio coverage rank
- 0%
- Share change
- +2,138,063
- Value change
- +$6,551,954
- Number of holders
- 41
- Shares outstanding
- 32,330,312
- SEC-reported price per share
- $6.41
- Insider filing price
- $6.41
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value is tracked under CUSIP 68235C206.
- 41 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 34 to 41 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $124,888,014 to $62,116,945.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 41 institutions filings for Q1 2026.
Security key
68235C206
Latest holder period
Q1 2026
13F holders
41
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
IMDX full holder history
Insight Molecular Diagnostics Inc. SEC filings
Insight Molecular Diagnostics Inc. company facts
Insight Molecular Diagnostics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68235C206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
IMDX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 40% | +6.2% | $41,828,418 | +$2,454,098 | 12,835,134 | +6.2% | Neal C. Bradsher | 23 Apr 2026 |
| AWM Investment Company, Inc. | 10% | +31% | $9,685,464 | +$5,257,076 | 2,857,069 | +119% | AWM Investment Company, Inc. | 31 Mar 2025 |
As of 31 Mar 2026, 41 institutional investors reported holding 18,938,098 shares of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX). This represents 59% of the company’s total 32,330,312 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
58%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BROADWOOD CAPITAL INC | 37% | 11,931,839 | +4.6% | 2.8% | $39,136,432 |
| AWM Investment Company, Inc. | 8.7% | 2,806,256 | -0.28% | 1% | $9,204,520 |
| PURA VIDA INVESTMENTS, LLC | 2.9% | 947,134 | 0% | 21% | $3,106,600 |
| Alyeska Investment Group, L.P. | 2.6% | 840,777 | 0.01% | $2,757,749 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 537,161 | 0% | 0% | $1,761,888 |
| HEIGHTS CAPITAL MANAGEMENT, INC | 1.2% | 392,545 | 0.36% | $1,287,548 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.81% | 262,053 | +13% | 0% | $860,170 |
| FNY Investment Advisers, LLC | 0.77% | 247,421 | +510% | 0.36% | $811,000 |
| BlackRock, Inc. | 0.42% | 135,345 | +3% | 0% | $443,932 |
| VANGUARD FIDUCIARY TRUST CO | 0.41% | 132,591 | 0% | 0% | $434,898 |
| Family Office Research LLC | 0.39% | 127,266 | 0.18% | $417,432 | |
| MILLENNIUM MANAGEMENT LLC | 0.32% | 103,470 | +69% | 0% | $339,382 |
| Ghisallo Capital Management LLC | 0.22% | 70,695 | 0.01% | $231,880 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.17% | 56,093 | -23% | 0% | $183,985 |
| STATE STREET CORP | 0.16% | 50,754 | +6.3% | 0% | $166,473 |
| NORTHERN TRUST CORP | 0.15% | 49,090 | +0.47% | 0% | $161,015 |
| MORGAN STANLEY | 0.11% | 36,088 | +0.49% | 0% | $118,369 |
| XTX Topco Ltd | 0.09% | 30,353 | 0% | $99,558 | |
| 683 Capital Management, LLC | 0.09% | 29,000 | -62% | 0.01% | $95,120 |
| Qube Research & Technologies Ltd | 0.08% | 25,230 | -11% | 0% | $82,754 |
| OSAIC HOLDINGS, INC. | 0.07% | 24,135 | -0% | 0% | $79,162 |
| UBS Group AG | 0.07% | 22,751 | +674% | 0% | $74,624 |
| Engineers Gate Manager LP | 0.06% | 18,253 | 0% | $59,870 | |
| Flatrock Wealth Partners LLC | 0.04% | 13,044 | 0.02% | $42,785 | |
| Point72 Asset Management, L.P. | 0.04% | 12,250 | 0% | $40,180 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
Q1 2026
Rows shown
1-12 of 12
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 18,938,098 | $62,116,945 | +$6,551,954 | $3.28 | 41 |
| 2025 Q4 | 16,651,600 | $124,888,014 | +$2,765,695 | $7.50 | 34 |
| 2025 Q3 | 16,282,884 | $54,051,121 | +$296,694 | $3.32 | 27 |
| 2025 Q2 | 15,248,594 | $46,050,393 | +$442,513 | $3.02 | 29 |
| 2025 Q1 | 16,047,858 | $49,105,818 | +$23,516,169 | $3.06 | 29 |
| 2024 Q4 | 8,368,639 | $19,916,902 | +$2,876,004 | $2.38 | 25 |
| 2024 Q3 | 7,107,091 | $20,255,014 | +$3,161,741 | $2.85 | 19 |
| 2024 Q2 | 5,990,280 | $17,670,609 | +$7,170,223 | $2.95 | 21 |
| 2024 Q1 | 3,559,240 | $10,429,392 | -$189,496 | $2.93 | 22 |
| 2023 Q4 | 3,624,342 | $9,059,295 | -$247,783 | $2.50 | 24 |
| 2023 Q3 | 3,718,862 | $11,617,455 | +$11,614,005 | $3.12 | 26 |
| 2023 Q2 | 15,000 | $3,450 | +$3,450 | $0.23 | 1 |